Peking University, April 11, 2023: Recently, the Chinese Medical Association issued the decision on granting the 2022 Chinese Medical Science and Technology Awards. PKU Medicine's research teams have been awarded four prizes, including one first prize, two second prizes, and one third prize. This achievement marks another significant milestone in the national medical and health industry's important science and technology award.

First Prize winning project: The key technology and clinical application of large bone and joint defect repair and reconstruction after bone tumor resection
First Accomplisher: Guo Wei, Peking University People’s Hospital

Guo Wei

The research group has addressed the global issue of repairing and reconstructing large bone and joint defects following bone tumor resection. Through innovative concepts and patented transformations, they have applied key technologies, including modular design and additive manufacturing. These efforts have significantly improved the prognosis and limb salvage function of patients with malignant bone tumors in China, with results that are at the forefront of international standards.

Second Prize winning project: Study on the neural mechanism and intervention of addiction and related mental diseases
First Accomplisher: Shi Jie, National Institute on Drug Dependence, Peking University 
 

Shi Jie

The project team utilized neuropharmacology, molecular biology, and medical psychology to systematically investigate the fundamental pathological mechanisms, risk factors, and intervention methods for addiction and related mental illnesses. The team proposed both non-pharmacological and pharmacological intervention approaches for eliminating pathological memory, specifically addiction, following non-conditional stimulus arousal. They also elucidated the key molecular and cellular mechanisms involved in the dynamic updating of pathological addiction memory. In addition, the team mapped out the neuron cluster activation associated with addiction memory following non-conditional stimulus arousal, identified the common genetic risk loci for multiple substance addictions, and discovered the key factors for reducing addiction-related mortality.

Second Prize winning project: Development of a new psoriasis drug aromatic hydrocarbon receptor modulator
First Accomplisher: Zhang Jianzhong, Peking University People’s Hospital

Zhang Jianzhong

 

Psoriasis is a chronic, inflammatory skin disease that is recurrent and currently lacks a cure, requiring long-term treatment. Collaborative research efforts have successfully developed the world's first-in-class new drug, benvitimod. In May 2019, the National Medical Products Administration approved the marketing of benvitimod cream in our country. This marks a significant breakthrough in the field of international psoriasis external drug research, which had not seen a new development in over 40 years.

Third Prize winning project: Recurrence mechanism and treatment strategy of liver tumor after radiofrequency ablation
First Accomplisher: Yang Wei, Peking University Cancer Hospital

Yang Wei

 

Psoriasis is a chronic and recurring inflammatory skin condition that currently lacks a cure and requires long-term treatment. However, collaborative research efforts have resulted in the development of a new drug called benvitimod, which is a first-in-class treatment. In May 2019, the National Medical Products Administration approved the marketing of benvitimod cream in our country. This approval marks a significant breakthrough in the field of international research on external drugs for psoriasis, which had not seen any new developments for over 40 years.

Congratulations to the recipients of the award!

Written by: Lang Lang
Edited by: Meng Bin
Source: Office of Scientific Research